Cargando…

Editorial: Patient-derived tumor models for drug development

Detalles Bibliográficos
Autores principales:	Sabaawy, Hatim E., Broggini, Massimo, Gupta, Shiv K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361608/ https://www.ncbi.nlm.nih.gov/pubmed/37483498 http://dx.doi.org/10.3389/fonc.2023.1243534

Ejemplares similares

Editorial: Harnessing the Power of Patient Derived Models of Cancer
por: Pine, Sharon R., et al.
Publicado: (2018)

Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy
por: Patrizii, Michele, et al.
Publicado: (2018)

Editorial: Tumor-Derived Extracellular Vesicles: Protocols, Models, and Clinical Evidence
por: Seigneuric, Renaud, et al.
Publicado: (2016)

Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
por: Gupta, Shiv K., et al.
Publicado: (2019)

Editorial: Enhancing Drug Delivery and Tumor Penetration
por: Tang, Yuxia, et al.
Publicado: (2021)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023)

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors
por: Cohen, Pascale A., et al.
Publicado: (2020)

Editorial: Roles of non-coding RNAs in tumor growth and development
por: Sharma, Gunjan, et al.
Publicado: (2022)

Editorial: Biological aspects of targeted drug discovery: Development of novel targets and/or chemotherapies, and drug repurposing
por: Kalra, Rajkumar Singh, et al.
Publicado: (2022)

Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
por: Sharick, Joe T., et al.
Publicado: (2020)

Role of mTOR and VEGFR Inhibition in Prevention of Metastatic Tumor Growth in the Spine
por: Kratzsch, Tobias, et al.
Publicado: (2020)

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures
por: Alcaniz, Joshua, et al.
Publicado: (2023)

Editorial: Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
por: Haupt, Ygal, et al.
Publicado: (2016)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Editorial: Stress response signaling in tumor development and its implications for cancer treatment
por: Wen, Danwan, et al.
Publicado: (2022)

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
por: Welby, John P., et al.
Publicado: (2019)

Editorial: Angiogenesis and tumor metastasis
por: Zhang, Qiang-Zhe, et al.
Publicado: (2023)

Editorial: Proteoglycans in the Tumor Microenvironment
por: Brunetti, Jlenia, et al.
Publicado: (2022)

Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response
por: Spiller, Erin R., et al.
Publicado: (2021)

Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays
por: Chadwick, Michelle, et al.
Publicado: (2020)

Patient-derived cancer models: Valuable platforms for anticancer drug testing
por: Genta, Sofia, et al.
Publicado: (2022)

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
por: Chiappa, Michela, et al.
Publicado: (2022)

Editorial: Tumor microenvironment in bladder cancer
por: Kusmartsev, Sergei, et al.
Publicado: (2023)

Editorial: Ferroptosis in malignant brain tumors
por: Yakubov, Eduard, et al.
Publicado: (2023)

Editorial: Advances in Combination Tumor Immunotherapy
por: Curran, Michael A., et al.
Publicado: (2015)

Editorial: Emerging Biomarkers in Genitourinary Tumors
por: Montironi, Rodolfo, et al.
Publicado: (2019)

Editorial: Epigenetic Regulation and Tumor Immunotherapy
por: Sun, Hongyin, et al.
Publicado: (2022)

Editorial: Nanomaterials and multimodal tumor therapy
por: Yang, Yongqi, et al.
Publicado: (2022)

Editorial: Megakaryocytes as regulators of tumor microenvironments
por: Migliaccio, Anna Rita, et al.
Publicado: (2022)

Editorial: Implementation of novel drugs and modern radiotherapy in the treatment of lymphoma patients
por: Levis, Mario, et al.
Publicado: (2023)

Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine
por: Pamarthy, Sahithi, et al.
Publicado: (2021)

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs
por: Liu, Yao, et al.
Publicado: (2022)

Editorial: The interconnection between the tumor microenvironment and immunotherapy in brain tumors
por: Qu, Chunrun, et al.
Publicado: (2023)

Editorial: Ubiquitin-Modifying Enzymes as Drug Targets and Biomarkers in Cancer
por: Bell, Jessica L., et al.
Publicado: (2021)

Editorial: Cancer Models
por: Breitenbach, Michael, et al.
Publicado: (2018)

The Application Progress of Patient-Derived Tumor Xenograft Models After Cholangiocarcinoma Surgeries
por: Wu, Jun, et al.
Publicado: (2021)

Editorial: Murine Models of Leukemia and Lymphoma
por: Cutucache, Christine E., et al.
Publicado: (2017)

Editorial: Impact of tumor microenvironment on lung cancer
por: Levantini, Elena
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ktvp2skb4f8ekg8obeodh29jvs